Target Trial Emulations of <scp>GLP</scp> ‐1 and Dual <scp>GLP</scp> ‐1/ <scp>GIP</scp> Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes

Treatment with tirzepatide and, to a lesser extent, semaglutide, in patients with T2D, was associated with a lower incidence of MALO compared with DPP4i after 2 years; largely driven by a reduction in the rates of compensated and decompensated cirrhosis. A reduction in MALO was not demonstrated with the use of liraglutide. These findings highlight a comparative benefit of tirzepatide (and semaglutide) versus DPP4i and should prompt more robust, longer-term randomised controlled studies to evaluate their role in preventing MALO in this increasingly prevalent patient population with co-existing T2D and MASLD.